RC-3095
Product Specifications
UNSPSC Description
RC-3095 is a bombesin/gastrin releasing peptide receptor (GRPR) antagonist[1]. RC-3095 exerts protective effects by reducing gastric oxidative injury in the arthritic mice[2].
Target Antigen
Bombesin Receptor
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/rc-3095.html
Solubility
H2O
Smiles
O=C([C@H]1CC(C(C=CC=C2)=C2N3)=C3CN1)N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@@H](C)C(N[C@@H](C(C)C)C(NCC(N[C@H](C(N[C@@H](CC(C)C)CN[C@H](C(N)=O)CC(C)C)=O)CC4=CN=CN4)=O)=O)=O)=O)CC5=CNC6=C5C=CC=C6)=O
Molecular Weight
1106.32
References & Citations
[1]Oliveira PG, et al. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Protective effect of RC-3095, an antagonist of the gastrin-releasing peptide receptor, in experimental arthritis. Arthritis Rheum. 2011 Oct;63(10):2956-65.|[2]Roesler R, et al. RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats. Eur J Pharmacol. 2004 Feb 13;486(1):35-41.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P0107/RC-3095-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P0107/
Clinical Information
Phase 2
CAS Number
138147-78-1
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1385896-01 0.02 mg (E-Coli)
Recombinant Lawsonia intracellularis (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase (fabZ)
Ask
View Details